Soleno Therapeutics Inc.
Soleno Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
Summary
On May 9, 2024, Soleno Therapeutics, Inc. reported its financial results for the first quarter of 2024, disclosing a net loss of approximately $21.4 million, or $0.59 per basic and diluted share, for the quarter. The company also announced key corporate updates including the receipt of Breakthrough Therapy Designation by the FDA for Diazoxide Choline Extended-Release (DCCR) in the treatment of Prader-Willi syndrome (PWS). Soleno had $307.2 million in pro forma cash reserves as of March 31, 2024, following a public offering that closed in May 2024. The press release can be found as Exhibit 99.1.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement